Efficacy of goserelin in ovarian function suppression and preservation for pre-and perimenopausal breast cancer patients: A systematic review Review
| Authors: | Chen, N.; Audi Blotta, D.; Kim, H. J.; Sayeed, S.; Cannon, J.; Osman, N.; Macrito, R.; Lambertini, M. |
| Review Title: | Efficacy of goserelin in ovarian function suppression and preservation for pre-and perimenopausal breast cancer patients: A systematic review |
| Abstract: | Background: Over the past few decades, the gonadotropin-releasing hormone agonist goserelin has been evaluated in ovarian function suppression (OFS) with adjuvant endocrine therapy and ovarian function preservation (OFP) during chemotherapy.Objective: The goal of this systematic literature review was to assess the efficacy of goserelin in OFS and OFP in combination with endocrine therapies and chemotherapy, respectively, in pre- and perimenopausal women with early-stage breast cancer.Design: This study is a systematic review.Data sources and methods: The literature search was conducted using PubMed. Prospective clinical studies evaluating the efficacy of goserelin in OFS or OFP in pre- or perimenopausal breast cancer were identified by four reviewers working in teams of two.Results: Twenty-nine studies were included in this systematic review. The addition of goserelin as OFS to adjuvant endocrine therapy generally resulted in significant benefits in disease-free survival. Studies have shown better OFP results among women 40 years or younger compared with older patients. Chemotherapy in association with goserelin for OFP resulted in a higher recovery rate of menses within 6-24 months, a shorter time for menstrual recovery, and significantly higher pregnancy rates when compared with cytotoxic therapy without goserelin. Hormonal recovery with higher anti-M & uuml;llerian hormone and estradiol levels, and lower follicle-stimulating hormone and luteinizing hormone levels occurred more frequently among women who received goserelin during chemotherapy as compared with those receiving cytotoxic therapy alone. The benefits of goserelin in OFP were more substantial among women 40 years or younger than in older patients.Conclusion: The findings of this systematic review highlight the benefits of adding goserelin to endocrine therapies for OFS and chemotherapy for OFP in early-stage breast cancer. Additionally, scientific data supporting OFS (including goserelin) in combination with newer agents such as cyclin-dependent kinase 4 and 6 inhibitors and bone-modifying agents are emerging. |
| Keywords: | chemotherapy; breast cancer; goserelin; tamoxifen; trial; women; efficacy; early-stage; ovarian; premenopausal patients; premenopausal; gnrh agonist; austrian breast; oncofertility; adjuvant endocrine therapy; cdk4/6 inhibitor; clinical end-points; bone-modifying agents; function suppression; plus zoledronic acid |
| Journal Title: | Therapeutic Advances in Medical Oncology |
| Volume: | 17 |
| ISSN: | 1758-8340 |
| Publisher: | Sage Publications Ltd. |
| Date Published: | 2025-01-01 |
| Start Page: | 17588359251319696 |
| Language: | English |
| ACCESSION: | WOS:001424758000001 |
| DOI: | 10.1177/17588359251319696 |
| PROVIDER: | wos |
| PMCID: | PMC11837078 |
| PUBMED: | 39975513 |
| Notes: | Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work